Inclusion Criteria

-INCLUSION CRITERIA:

1. Patients must have histologically confirmed (by the NIH pathology department) solid
tumor malignancy or lymphoma that is metastatic or unresectable for which standard
curative measures do not exist, or are associated with minimal patient survival
benefit.

2. Patients must have measurable or evaluable disease.

3. Patients must have completed any chemotherapy or biologic therapy greater than or
equal to 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin
C, or UCN-01). Patients must be greater than or equal to 2 weeks since any prior
administration of study drug in a exploratory IND/Phase Zero study. Patients must be
greater than or equal to 1 month since any prior radiation or major surgery. Patients
must have recovered to eligibility levels from prior toxicity or adverse events.
However, patients receiving bisphosphonates for any cancer or undergoing androgen
deprivation therapy for prostate cancer are eligible for this therapy.

4. Age greater than or equal to 18 years.

5. The Eastern Cooperative Oncology Group (ECOG) performance status less than or equal
to 2 (Karnofsky greater than or equal to 60%).

6. Life expectancy greater than 3 months.

7. Patients must have normal or adequate organ and marrow function as defined below:

- Absolute neutrophil count greater than or equal to 1,500/microL.

- Platelets greater than or equal to 100,000/microL.

- Total bilirubin within less than or equal to 1.5 normal institutional limits.

- AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of
normal.

- creatinine less than 1.5 x upper limit of normal

OR

-creatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with
creatinine levels greater than or equal to 1.5 times upper limit of normal.

We will allow patients with Gilbert's syndrome with total bilirubin up to 2.5 mg/dL.

8. The effects of batracylin on the developing human fetus are unknown. For this
reason, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control or abstinence) prior to
study entry, for the duration of study participation, and for 2 months after
discontinuation from the study. Women of child bearing potential must have a
negative pregnancy test in order to be eligible. Should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately. Because there is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with
batracylin, breastfeeding should be discontinued if the mother is treated with
batracylin.

9. Patients must have a slow acetylator NAT2 genotype defined as NAT2 5, NAT2 6, NAT2 7,
or NAT2 14. Theoretically slow acetylators will have lower Ac-BAT concentrations. A
number of different polymorphisms in the NAT2 give rise to amino acid substitutions,
and these have been demonstrated to result in absence of catalytic activity in vitro
(http://www.louisville.edu/medschool/pharmacology/NAT.html). Screening for the four
variant alleles (NAT2 5, NAT2 6, NAT2 7 and NAT2 14) results in the detection of the
vast majority of Caucasian slow acetylators, though additional alleles are also
common in other ethnic groups. The precise percentage of slow acetylators also varies
with ethnic origin, ranging from 90% in North Africans to less than 10% in many Asian
populations, with a frequency of 50% in Caucasians. The incidence of fast
acetylators (potentially with increased toxicity) is as follow: 50% among Caucasians,
50% among Africans, 90% among Japanese, and 20% among Egyptians. We plan to select
the slow acetylators NAT2 subjects and determine the batracylin MTD in this
population. The screening will occur prior to the study start and before patients
sign the informed consent form. Cogenics will be performing the NAT2 analysis.

10. Ability to understand and the willingness to sign a written informed consent
document.

EXCLUSION CRITERIA:

1. Patients receiving any other investigational agents.

2. Patients with known brain metastases are excluded from this clinical trial, with the
exception of patients whose brain metastatic disease status has remained stable for
greater than or equal to 6 months after treatment of the brain metastases, without
steroids or anti-seizure medications. These patients may be enrolled at the
discretion of the principal investigator.

3. Patients with clinically significant illnesses which could compromise participation
in the study, including, but not limited to, active or uncontrolled infection, immune
deficiencies or confirmed diagnosis of HIV infection, Hepatitis B, Hepatitis C,
uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart
failure, unstable angina pectoris, myocardial infarction within the past 6 months,
uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements.

Inclusion of Women and Minorities

Both men and women, and members of all races and ethnic groups, are eligible for this
trial.